Tus%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

# TUSQ-QD ## Overview TUSQ-QD is a fixed-dose combination product containing **tuberculosis (TB) medications**. The exact composition can vary, but it typically includes several first-line anti-TB agents. ## Primary Indications Treatment of **active tuberculosis disease** in accordance with established treatment guidelines. ## Adult Dosing Dosing is highly individualized based on the phase of treatment, patient weight, and drug susceptibility testing. Common regimens include: * **Intensive Phase (typically 2 months):** Usually involves a combination of isoniazid, rifampin, pyrazinamide, and ethambutol. Specific doses depend on weight and the combination product formulation. * **Continuation Phase (typically 4-7 months or longer):** Often involves isoniazid and rifampin, or other agents depending on clinical response and susceptibility. **Exact dosing must be determined by established TB treatment guidelines (e.g., CDC, WHO) and patient-specific factors.** ## Pediatric Dosing Pediatric dosing also depends on weight and the specific TB treatment regimen. Fixed-dose combination products are available for children, with dosages adjusted for age and weight categories. **Refer to pediatric TB treatment guidelines for precise dosing recommendations.** ## Dose Adjustments * **Renal Impairment:** Dose adjustments may be necessary for certain components, particularly ethambutol and isoniazid, depending on the degree of renal impairment. * **Hepatic Impairment:** Close monitoring for hepatotoxicity is crucial. Dose adjustments or discontinuation of certain agents may be required. ## Contraindications * **Hypersensitivity** to any component of the formulation. * **Severe hepatic impairment** (may be a contraindication for pyrazinamide). * Specific contraindications for individual components (e.g., optic neuritis for ethambutol). ## Adverse Effects Common adverse effects can include: * Hepatotoxicity (most serious) * Gastrointestinal upset (nausea, vomiting, abdominal pain) * Peripheral neuropathy (isoniazid) * Ocular toxicity (ethambutol - visual disturbances, decreased visual acuity, color vision changes) * Gout exacerbation (pyrazinamide) * Orange discoloration of body fluids (rifampin) * Drug rash, fever ## Key Drug Interactions * **CYP450 interactions:** Rifampin is a potent inducer of CYP450 enzymes, affecting metabolism of many drugs (e.g., anticoagulants, antifungals, corticosteroids, oral contraceptives, antiretrovirals). * **Antacids:** May decrease absorption of certain components. * **Antiretrovirals:** Numerous interactions are possible. ## Monitoring * **Baseline and periodic liver function tests (LFTs)** are essential due to risk of hepatotoxicity. * **Visual acuity and color vision testing** for ethambutol. * **Uric acid levels** (especially with pyrazinamide). * **Renal function tests.** * **Peripheral neuropathy symptoms.** * **Adherence monitoring** is critical for treatment success. ## Clinical Pearls * TUSQ-QD is designed to improve adherence by combining multiple medications into a single dosage form. * Treatment duration for TB is lengthy and requires strict adherence. * Hepatotoxicity is a significant concern; patients should be educated to report any signs of liver dysfunction (jaundice, dark urine, abdominal pain, fatigue). * Ethambutol requires ophthalmologic monitoring. * Rifampin can permanently stain soft contact lenses. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details and to verify dosing and safety information before making clinical decisions.